Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review

Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review

Purpose. To evaluate the effectiveness of Janus kinase (JAK) inhibitors for the treatment of patients with autoimmune disease and associated inflammatory ocular diseases. Methods. We identified relevant literature by screening the MEDLINE, PubMed, and Cochrane databases for randomized controlled tri...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ji Wen, Huifang Hu, Menglin Chen, Hang Yang, Yi Zhao, Yi Liu
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2021/2324400
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Loss of Cardiomyocyte Janus Kinase 1 (Jak1) Causes Cardiomyopathy
by: Arasakumar Subramani, et al.
Published: (2025-06-01)

Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)

Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review
by: Yu Liu, et al.
Published: (2025-12-01)

Intraocular infections following biologicals and Janus Kinase inhibitors
by: Parthopratim Dutta Majumder, et al.
Published: (2025-08-01)

Janus kinase inhibitors – a role for the treatment of cutaneous T-cell lymphomas?
by: Sarah E. Packer, et al.
Published: (2025-08-01)

Janus Kinase 1 (Jak1) Palmitoylation Regulates Cardiomyocyte Cytokine Receptor Trafficking and Stat3 Signaling
by: Kobina Essandoh, et al.
Published: (2025-06-01)

Janus kinase inhibitors for alopecia areata: a review of clinical data
by: Yutong Sun, et al.
Published: (2025-05-01)

Janus kinase 1 inhibitor abrocitinib for isolated nail lichen planus: a case report and literature review
by: Juan He, et al.
Published: (2024-12-01)

Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis
by: Grace Xiong, BHSc, et al.
Published: (2025-04-01)

Can Janus kinase inhibitors be used to treat immune checkpoint inhibitor associated adverse events?
by: Jürgen Braun, et al.
Published: (2024-11-01)

Comparison of T cell response to vaccination in rheumatic patients treated with Janus kinase inhibitors and TNF inhibitors
by: Sebastian Hüper, et al.
Published: (2025-07-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
by: E. L. Nasonov, et al.
Published: (2019-03-01)

Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
by: E. L. Nasonov, et al.
Published: (2022-05-01)

Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review
by: Olimpia Wiciun, et al.
Published: (2025-05-01)

The FDA has expanded the indications for the appointment of an oral janus kinase 1 inhibitor
by: article Editorial
Published: (2023-03-01)

Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction
by: Florian Fischer, et al.
Published: (2025-05-01)

RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
by: Vibeke Strand
Published: (2021-04-01)

Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
by: Huibin Yang, et al.
Published: (2025-12-01)

Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis
by: Bai-lin Chen, et al.
Published: (2024-12-01)

Biomimetic polydopamine loaded with janus kinase inhibitor for synergistic vitiligo therapy via hydrogel microneedles
by: Chunying Li, et al.
Published: (2025-01-01)

A Novel Dual Bruton's Tyrosine Kinase/Janus Kinase 3 Inhibitor Wj1113 and its Therapeutic Effects on Rheumatoid Arthritis
by: Chunyu Zhang, et al.
Published: (2025-07-01)

Aggressive cutaneous squamous cell carcinoma in a patient on Janus-kinase inhibitor therapy
by: Ana M. Aragon Sierra, MD, et al.
Published: (2025-03-01)

Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib
by: Luo Y, et al.
Published: (2025-05-01)

Treatment of Hailey-Hailey disease with the Janus kinase inhibitor abrocitinib: A case report
by: Molly Gunyon, et al.
Published: (2025-06-01)

Impact of Janus kinase inhibitors and methotrexate on interstitial lung disease in rheumatoid arthritis patients
by: Shota Kurushima, et al.
Published: (2024-12-01)

Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012-2023.
by: Xiaoyan Zhong, et al.
Published: (2025-01-01)

Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
by: Yachar Dawudi, et al.
Published: (2025-01-01)

Tumor necrosis factor inhibitors versus janus kinase inhibitors in patients with incomplete response to methotrexate in rheumatoid arthritis
by: Kunal Chandwar, et al.
Published: (2023-01-01)

The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)
by: Yu. A. Lushpaeva
Published: (2025-04-01)

Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
by: A. O. Bobkova, et al.
Published: (2023-07-01)

Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
by: Chino Ogbutor, BA, et al.
Published: (2025-10-01)

A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
by: Dmitry Evgenyevich Karateev
Published: (2014-03-01)

Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility (JAKPPPOT) trial protocol
by: Weiyu Ye, et al.
Published: (2025-08-01)

Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis
by: Jin-Won Kwon, et al.
Published: (2024-04-01)

Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report
by: Zhang Y, et al.
Published: (2025-06-01)

Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.
by: Konstantinos Ouranos, et al.
Published: (2024-01-01)

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
by: Camille M. Powers, et al.
Published: (2024-12-01)

Case report: Effectiveness of Janus kinase inhibitors in the management of isolated noninfectious uveitis: a case series
by: Nina Vidic Krhlikar, et al.
Published: (2025-03-01)

Epigenomic landscapes define differential Janus kinases inhibitor sensitivity in IFN-γ-primed human macrophages
by: Geunho Kwon, et al.
Published: (2025-05-01)